New hope for Hard-to-Treat cancers?

NCT ID NCT04419532

Ongoing Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have come back or spread and no longer respond to standard treatments. The main goal is to check the drug's safety and find the right dose. This is a first-in-human trial, so it focuses on side effects and how the drug moves through the body, not on curing the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer esophageal cancer gastric cancer head and neck cancer melanoma metastatic malignant neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER METASTATIC SOLID TUMOR SOLID TUMOR

Contacts and locations

Locations

Cancer Institute Hospital of JFCR

Kōtoku, 135-8550, Japan
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
National Cancer Center Hospital

Chūōku, 104-0045, Japan
National Cancer Center Hospital East

Kashiwa, 277-8577, Japan
Princess Margaret Cancer Center

Toronto, Ontario, M5G 2C1, Canada
University of Cincinnati Cancer Center

Cincinnati, Ohio, 45219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.